Research ArticleProceedings of the 2017 Viral Clearance Symposium
Proceedings of the 2017 Viral Clearance Symposium: Conclusion
Stefan Hepbildikler, Sarah Johnson and Johannes Bluemel
PDA Journal of Pharmaceutical Science and Technology September 2018, 72 (5) 525-530; DOI: https://doi.org/10.5731/pdajpst.2018.009084
Stefan Hepbildikler
1Roche Pharma Bioprocess Development, Nonnenwald 2, 82377 Penzberg, Germany;
Sarah Johnson
2Center for Drug Evaluation and Research, Office of Biotechnology Products, U.S. Food and Drug Administration; and
Johannes Bluemel
3Paul-Ehrlich-Institut, Virology Department, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 72, Issue 5
September/October 2018
Proceedings of the 2017 Viral Clearance Symposium: Conclusion
Stefan Hepbildikler, Sarah Johnson, Johannes Bluemel
PDA Journal of Pharmaceutical Science and Technology Sep 2018, 72 (5) 525-530; DOI: 10.5731/pdajpst.2018.009084
Jump to section
- Article
- Abstract
- Introduction
- Session 1.1: Upstream Mitigation—Cell Bank and Bulk Harvest Testing
- Session 1.2: Upstream Risk Mitigation—Virus Barrier Filter and High-temperature Short-Time Treatment
- Session 2.1: Downstream Unit Operations—Virus Filtration/Inactivation
- Session 2.2: Downstream Unit Operations—Purification Unit Operations
- Session 3: Resin Lifetime
- Session 4: Submission Strategies
- Session 5: Facility Risk Mitigation
- Session 6: Continuous Processing
- Disclaimer
- Conflict of Interest Declaration
- References
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- No citing articles found.